These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15452762)

  • 1. Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees.
    Anell A
    Eur J Health Econ; 2004 Feb; 5(1):28-35. PubMed ID: 15452762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?
    Anell A; Persson U
    Eur J Health Econ; 2005 Sep; 6(3):274-9. PubMed ID: 15968561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stakeholder involvement in expensive drug recommendation decisions: an international perspective.
    Rosenberg-Yunger ZR; Thorsteinsdóttir H; Daar AS; Martin DK
    Health Policy; 2012 May; 105(2-3):226-35. PubMed ID: 22226141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating economic evaluations into decision-making: the Ontario experience.
    Laupacis A
    Med Care; 2005 Jul; 43(7 Suppl):15-9. PubMed ID: 16056004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
    Franken M; Koopmanschap M; Steenhoek A
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs.
    Husereau D; Dempster W; Blanchard A; Chambers J
    Value Health; 2014 Dec; 17(8):888-94. PubMed ID: 25498784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United Kingdom.
    Kanavos P; Trueman P; Bosilevac A
    Int J Technol Assess Health Care; 2000; 16(4):1179-92. PubMed ID: 11155837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of health economic information by reimbursement authorities.
    Drummond MF
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii60-3. PubMed ID: 14585919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.
    Persson U; Willis M; Odegaard K
    Eur J Health Econ; 2010 Apr; 11(2):195-203. PubMed ID: 19639352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pricing of pharmaceuticals. Assessing the pricing potential by a pricing matrix model.
    Nuijten MJ; Kosa J
    Eur J Health Econ; 2004 Jun; 5(2):110-5. PubMed ID: 15452745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pricing and reimbursement of drugs in Ireland.
    Barry M; Tilson L; Ryan M
    Eur J Health Econ; 2004 Jun; 5(2):190-4. PubMed ID: 15452757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of economic evaluation in local health care decision-making in England: a qualitative investigation.
    Eddama O; Coast J
    Health Policy; 2009 Mar; 89(3):261-70. PubMed ID: 18657336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
    Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
    Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priority setting for orphan drugs: an international comparison.
    Rosenberg-Yunger ZR; Daar AS; Thorsteinsdóttir H; Martin DK
    Health Policy; 2011 Apr; 100(1):25-34. PubMed ID: 20961647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European drug reimbursement systems' legitimacy: five-country comparison and policy tool.
    Cleemput I; Franken M; Koopmanschap M; le Polain M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):358-66. PubMed ID: 22980497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?
    Wonder M; Dunlop S
    Value Health; 2015 Jun; 18(4):467-76. PubMed ID: 26091601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.